ESMO 2025 | What is the importance of CTLA-4 inhibition in treating melanoma?
Paolo Ascierto, MD, Istituto Tumori Fondazione Pascale, Naples, Italy, highlights the significance of CTLA-4 as a checkpoint inhibitor in the treatment of melanoma. CTLA-4 inhibition can benefit around half of patients with melanoma, potentially leading to a cure, and preliminary results from triplet therapies have shown promising results. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the CTLA-4, it’s an important drug. It was the first checkpoint inhibitor that changed the history of melanoma. And it’s still important because in combination to get around the PD-1 tumor in melanoma is responsible for the 50% of patients that can get a benefit, can be cured in the field of melanoma. So it’s an important drug. We know that even with the triplet melanoma, the addition of IP to Nivolumab showed interesting results with the 70% of patients still alive, 20% more...
So the CTLA-4, it’s an important drug. It was the first checkpoint inhibitor that changed the history of melanoma. And it’s still important because in combination to get around the PD-1 tumor in melanoma is responsible for the 50% of patients that can get a benefit, can be cured in the field of melanoma. So it’s an important drug. We know that even with the triplet melanoma, the addition of IP to Nivolumab showed interesting results with the 70% of patients still alive, 20% more. Preliminary results, but still interesting. So I believe that this drug, even if the toxicity is high, is still important because of the memory effect that we have with anti-CTLA-4. It’s something that can be really useful for patients because patients can be cured.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
